YC-supported reaction is applied to accelerate drug production AI

Artificial intelligence continues to confuse everything in chemistry. Be smart: YC-supported Cambridge, England based React Uses AI to speed up chemical production – the main step in bringing new medications to new drugs.

After a promising drug in the laboratory, Pharma companies should be able to produce more amounts of material to conduct clinical trials. This is a “AI copilot” ai copylot, “AI copilot”, which is a “AI copilot” to find the best method for preparing up to 30x, is reacting.

“Drugs are like cooking really like cooking,” he said, “You must find the best recipe to make a medication that has a high product of high purity and a high product.”

According to him, the industries have been relied on what has been linked to this “development” for years. Add automation to add automation, provides a way to reduce how many iteration periods are required to land a solid recipe for a drug production.

The beginning thinks that “ai-” can predict “the Ideal experience” – in two years, “he said,” It thinks that information about EU’s experience is further fed. “

Startup machine learning AI models can still save the basic savings by reducing how much iteration is required for the passage of this bit of the drug development chain.

Cut through the tedium

“An inspiration for this, I have worked in the great pharma and saw how tiring and tried the whole industry,” the five-year academic researches “Automate the chemical synthesis managed by the EU” – “a simple program” – a “simple program”.

Reactwise’s product is “Thousands” reactions in the “Thousands” reactions in the starting laboratory in the starting laboratory in the starting laboratory to feed the data points to feed AI-based forecasts. Pomberger, in the beginning, in the laboratory, allowing the “High Transfer Strip screen” method, which allows you to quickly screen 300 reactions, it uses a “high transmission option” method that allows you to accelerate the process of capturing information for AI.

“At Pharma … there are one or two handful of reactions, reaction, repeatedly used,” he said. “We do, we create thousands of data points for this most suitable reactions, which we can understand the chemistry in our side. And then there is no need to start with a client, when a customer should develop an expandable process.”

The beginning began the process of seizing the types of reactions to train the EU in August last August, and Pomberger said it would be completed by the summer. It works to cover 20,000 chemical databases for “covering the most important reactions”.

“To get a data point in a traditional way, it usually usually takes a chemistry of up to three days,” said, “So it is expensive to evaluate data.”

To date, it is directed to the production processes for “small molecule medications” that can be used in drugs targeting any diseases of Pomberer. However, it also noted that technology will be applied in other subjects, and the company is working with two materials in the development of polymer drug supplies.

Reactwis’s automation game includes a program that can open an interface with robot laboratory equipment to further increase the production of medicines. However, it is directed to the purely sales program; The Robot Lab itself is not a manufacturer itself. On the contrary, the robot is added to another sim added to the summer to offer robot laboratory equipment.

In July 2024, the beginning of England, 12 pilot tests working with software and pharma companies. Pomberger said that they expect the first conversions – the subscription program expects the full-scale placement – the end of the year. These trials, which reacted, include some major pharma players, without disclosing the names of all firms.

Pre-Seed Finance

Reactwis explains the full details of the pre-seed increase in $ 3.4 million, which applies to TechCrunch at the beginning.

This figure includes support previously YC ($ 500,000) and disclosed from A Innovation England Grant Close to £ 1.2 million (about $ 1.6 million). The rest of the finances ($ 1.5 million), the capitalists of the anonymous enterprise and angel investors, reacted are called “to develop AI-based, sustainable pharmaceutical production.”

When paying a very narrow, very narrow, very narrow way in a certain part of Pomberger’s drug development chain, here can make a meaningful difference in acceleration, patients need to take new medicine.

“Let’s look at the beginning of a drug: 10-12 years. The development of the process lasts by 1.5 to two years. Basically, if the workflows can be reduced by an average of 60%, we can get an idea of ​​how much it affects.”

At the same time, other beginnings To apply AI to different aspects of drug developmentIn the first place, including the identification of interesting chemicals, so it is likely to have complex effects because more automation updates are attended.

However, when it comes to drug production, Pomberger claims that the resuscitation is ahead. “We were the first to solve it,” he said.

Starting competes with a legacy program using statistical approaches such as JMP. He said that there were several people who applied AI to accelerate drug production, but the ability to access high quality data sets on chemical reactions of reactions gives rise to high quality data sets.

“We have the opportunity and are currently these high quality data are only at home,” he said. “Most of our competitors provide software. Customers are asked based on instructions based on entrances.

“But we offer these alleged models from all of us, and it is very strong, because it is only a customer. At this point, no one is something nobody. “